Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia.

abstract：:Acute myeloid leukemia (AML) blast cells (BC) express antigens that are commonly found on their normal counterparts. The leukemia colony-forming cell (L-CFC) subpopulation, identified by its ability to form leukemia colonies in vitro, is thought to be the stem cell population that produces BC. To ascertain the associa...

journal_title：Bone marrow transplantation

authors： Howell AL,Stukel TA,Bloomfield CD,Ball ED

更新日期：1992-09-01 00:00:00

abstract：:Thrombotic microangiopathy (TMA) is a significant complication after hematopoietic stem-cell transplantation (HSCT); however, there is little information on it following reduced-intensity cord blood transplantation (RI-CBT). We reviewed the medical records of 123 adult patients who received RI-CBT at Toranomon Hospita...

journal_title：Bone marrow transplantation

authors： Narimatsu H,Kami M,Hara S,Matsumura T,Miyakoshi S,Kusumi E,Kakugawa Y,Kishi Y,Murashige N,Yuji K,Masuoka K,Yoneyama A,Wake A,Morinaga S,Kanda Y,Taniguchi S

更新日期：2005-09-01 00:00:00

abstract：:In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. Of these, 11 had previously achieved hematologic remission and cytogenetic improvement after alpha-2b in...

journal_title：Bone marrow transplantation

authors： Lo Coco F,Mandelli F,Diverio D,Alimena G,De Fabritiis P,Meloni G,Cedrone M,Frontani M,Guerrasio A,Saglio G

更新日期：1990-10-01 00:00:00

abstract：:Progression of Philadelphia-negative myeloproliferative (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) to acute myeloid leukemia (AML) is an adverse event in the course of the disease. Although allogeneic hematopoietic SCT (allo-SCT) is considered as the only curative therapy, few data exist on the ou...

journal_title：Bone marrow transplantation

authors： Cahu X,Chevallier P,Clavert A,Suarez F,Michallet M,Vincent L,Vigouroux S,Blaise D,Mariette C,Bilger K,Robin M,Yakoub-Agha I,Peffault de Latour R,Mohty M

更新日期：2014-06-01 00:00:00

abstract：:Allo-SCT using unrelated donors is a curative treatment for patients with hematological disorders. The best donor is one matched for 10/10 HLA alleles, however studies have shown an additional survival benefit when considering other genetic factors. It has been shown that a six-nucleotide insertion/deletion polymorphi...

journal_title：Bone marrow transplantation

authors： Shaw BE,Lee F,Krishnamurthy S,Byrne JL,Seedhouse C,Mayor NP,Maldonado-Torres H,Saudemont A,Marsh SG,Madrigal JA,Russell NH

更新日期：2015-02-01 00:00:00

abstract：:Large registry studies have shown superior disease-free survival (DFS) with matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT) over chemotherapy alone for patients with B-precursor acute lymphoblastic leukemia (ALL) and a late BM relapse. As most of these patients will not have an MSD...

journal_title：Bone marrow transplantation

authors： Beck JC,Cao Q,Trotz B,Smith AR,Weigel BJ,Verneris MR,Burke MJ

更新日期：2011-07-01 00:00:00

abstract：:This retrospective study was conducted to determine whether the total number of nucleated cells (TNC)/kg collected at marrow harvest was associated with outcome in 151 patients with acute myelogenous leukemia (AML) who received an autologous purged (n = 67) or non-purged (n = 84) marrow transplant. At the time of tran...

journal_title：Bone marrow transplantation

authors： Demirer T,Gooley T,Buckner CD,Petersen FB,Lilleby K,Rowley S,Sanders J,Storb R,Appelbaum FR,Bensinger WI

更新日期：1995-06-01 00:00:00

abstract：:Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who...

journal_title：Bone marrow transplantation

authors： Imahashi N,Suzuki R,Fukuda T,Kakihana K,Kanamori H,Eto T,Mori T,Kobayashi N,Iwato K,Sakura T,Ikegame K,Kurokawa M,Kondo T,Iida H,Sakamaki H,Tanaka J,Kawa K,Morishima Y,Atsuta Y,Miyamura K

更新日期：2013-01-01 00:00:00

abstract：:Fourteen children with high risk leukaemia received allogeneic bone marrow transplants from HLA-identical MLC-compatible sibling donors. All bone marrows were T cell depleted and a T cell addback was prepared from the donor's peripheral blood so that the mean total number of CD3+ cells given was 2.6 (1.0-4.1) x 10(5)/...

journal_title：Bone marrow transplantation

authors： Potter MN,Pamphilon DH,Cornish JM,Oakhill A

更新日期：1991-11-01 00:00:00

abstract：:Allogeneic BMT for patients with acute myeloid leukemia (AML) is presently a reference therapy. The indications for this therapy mainly rely upon prognostic factors, and their importance is constantly reassessed. To examine the impact of time from diagnosis to transplant on survival and leukemia-free survival (LFS), w...

journal_title：Bone marrow transplantation

authors： Jourdan E,Maraninchi D,Reiffers J,Gluckman E,Rio B,Jouet JP,Michallet M,Molina L,Archimbaud E,Harousseau JL,Ifrah N,Attal M,Guilhot F,Kuentz M,Guyotat D,Pico JL,Dauriac C,Legros M,Dreyfus F,Bordigoni P,Leblond V,

更新日期：1997-05-01 00:00:00

abstract：:The role of high-dose therapy and autologous stem cell transplantation (ASCT) in the treatment of patients with Ewing's sarcoma (EWS) remains uncertain. From November 1985 to September 1994, 13 patients aged 16-30 years (median 20.5) received high-dose melphalan (HDM) 140-200 mg/m2 +/- 500 cGy TBI followed by ASCT for...

journal_title：Bone marrow transplantation

authors： Stewart DA,Gyonyor E,Paterson AH,Arthur K,Temple W,Schachar NS,Klassen J,Brown C,Russell JA

更新日期：1996-08-01 00:00:00

abstract：:Acute decompensating cardiomyopathy induced by cyclophosphamide is usually irreversible. To investigate the clinical course and the outcome of therapy, 13 patients (1.7%) with grade III acute cardiomyopathy and hypotension who were treated with ablative transplant regimens between January 1980 and September 1995 were ...

journal_title：Bone marrow transplantation

authors： Lee CK,Harman GS,Hohl RJ,Gingrich RD

更新日期：1996-09-01 00:00:00

abstract：:Limited information is available regarding the incidence and features of lymphocyte expansions after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Large granular lymphocytes (LGL) expansions have been reported after bone marrow or peripheral blood, but not after unrelated cord blood (UCB) allo-HSCT, ...

journal_title：Bone marrow transplantation

authors： Le Bris Y,Guillaume T,Ménard A,Illiaquer M,Martin J,Malard S,Duquesne A,Peterlin P,Debord C,Robillard N,Eveillard M,Wuillème S,Delaunay J,Mohty M,Garnier A,Moreau P,Béné MC,Chevallier P

更新日期：2017-06-01 00:00:00

abstract：:The use of mobilized peripheral blood (PB) stem cells for autologous transplantation initially generated much enthusiasm because of enhanced engraftment in comparison to marrow stem cells and avoidance of general anesthesia for the donor. Its application to the allogeneic setting seemed inevitable. For obvious ethical...

journal_title：Bone marrow transplantation

authors： Gyger M,Stuart RK,Perreault C

更新日期：2000-07-01 00:00:00

abstract：:Intermediate-dose salvage therapy is frequently given for relapsed and resistant lymphomas and is usually intensely myelosuppressive. In an attempt to reduce the haematological toxicity of miniBEAM, one of the commonly used salvage regimens, peripheral blood stem cell (PBSC) support was given to 21 consecutive patient...

journal_title：Bone marrow transplantation

authors： Fielding AK,Goldstone AH,Sullivan AM,Watts MJ,Jamieson E,Linch DC

更新日期：1996-09-01 00:00:00

abstract：:The p19 dimer of interleukin 23 (IL-23) has been reported to have a major role in the pathogenesis of many experimental and clinical autoimmune diseases and may also have a prominent role in transplantation. We reasoned that deficiency of p19 in the allogeneic donor transplant might reduce the inflammation caused by a...

journal_title：Bone marrow transplantation

authors： Thompson JS,Chu Y,Glass JF,Brown SA

更新日期：2010-04-01 00:00:00

abstract：:Current graft-versus-host disease (GVHD) prophylaxis is not uniformly successful. Since the development of GVHD has a profound impact on transplant success, treatment is required. The mainstay of therapy has been glucocorticoids (steroids), along with anti-thymocyte globulin, cyclosporine, monoclonal antibodies, and a...

journal_title：Bone marrow transplantation

authors： Deeg HJ,Henslee-Downey PJ

更新日期：1990-07-01 00:00:00

abstract：:Fetus-to-fetus transplantation has been suggested for the treatment of hemoglobinopathies in utero. However, dissimilar results have to date been obtained by different groups. We describe a case in which fetus-to-fetus transplantation in HLA-identical twins was performed at the 19th week of gestation by infusion of 0....

journal_title：Bone marrow transplantation

authors： Orlandi F,Giambona A,Messana F,Marino M,Abate I,Calzolari R,Damiani F,Jakil C,Renda M,Dieli F,Buscemi F,Westgren M,Ringden O,Maggio A

更新日期：1996-09-01 00:00:00

abstract：:This report summarizes the Spanish experience of 62 cases of allogeneic transplantation of purified CD34+ cells from peripheral blood. HLA-identical sibling donors received G-CSF. After leukapheresis, peripheral blood progenitor cells were purified using one of two methods: Ceprate (n = 38), or Isolex 300 (n = 24). Si...

journal_title：Bone marrow transplantation

authors： Urbano-Ispizua A,Solano C,Brunet S,de la Rubia J,Odriozola J,Zuazu J,Figuera A,Caballero D,Martínez C,García J,Sanz G,Torrabadella M,Alegre A,Pérez-Oteiza J,Jurado M,Oyonarte S,Sierra J,García-Conde J,Rozman C

更新日期：1998-06-01 00:00:00

abstract：:A 55-year-old man with acute myeloid leukemia in second relapse presented 4 months after haploidentical CD34+-selected hematopoietic stem cell transplantation (HSCT) with symmetric, progressive neurological deficits of the lower extremities. Although there was no molecular evidence for drug resistance in the cerebral-...

journal_title：Bone marrow transplantation

authors： Zeiser R,Grüllich C,Bertz H,Pantazis G,Hufert FT,Bley TA,Finke J

更新日期：2004-01-01 00:00:00

abstract：:It is unclear whether supplemental glutamine is of benefit in haematopoietic stem cell transplantation (HSCT). We performed a systematic review and meta-analyses using Cochrane methodology. Seventeen randomized controlled trials (RCTs) were found. There was considerable heterogeneity between studies in terms of patien...

journal_title：Bone marrow transplantation

authors： Crowther M,Avenell A,Culligan DJ

更新日期：2009-10-01 00:00:00

abstract：:The role of amifostine in the prevention of cyclophosphamide-induced hemorrhagic cystitis (HC) was evaluated in the rat model. Urinary bladders from control rats that received no drugs (group I) were compared with those from rats receiving cyclophosphamide alone at a dose of 150 mg/kg (group II), and two other groups ...

journal_title：Bone marrow transplantation

authors： Srivastava A,Nair SC,Srivastava VM,Balamurugan AN,Jeyaseelan L,Chandy M,Gunasekaran S

更新日期：1999-03-01 00:00:00

abstract：:Lineage-specific chimerism studies are commonly obtained at several time points after nonmyeloablative hematopoietic cell transplantation to assess the tempo and degree of engraftment, and to monitor graft rejection. For patients who receive myeloablative transplants, the value of frequent chimerism analyses using sen...

journal_title：Bone marrow transplantation

authors： Doney K,Loken M,Bryant E,Smith A,Appelbaum F

更新日期：2008-08-01 00:00:00

abstract：:Over more than three decades, The Anthony Nolan Trust (ANT) has provided an unrelated donor (UD) for over 4000 children and adults lacking a suitable family member donor, and has remained at the forefront of developments in haematopoietic stem cell transplantation (HSCT) and bone marrow register management. These thre...

journal_title：Bone marrow transplantation

authors： Duarte RF,Pamphilon D,Cornish J,Shaw BE,Samson D,Craddock C,Marks D,Mufti GJ,Powles RL,Apperley JF,Madrigal JA,Goldman JM

更新日期：2006-05-01 00:00:00

abstract：:Relapse rates in patients after autologous bone marrow transplantation (BMT) for acute myeloid leukemia (AML) continue to be high despite the use of aggressive conditioning regimens. Based on studies in the murine system a clinical protocol was developed that utilizes immunotherapy to obtain a graft-versus-leukemia (G...

journal_title：Bone marrow transplantation

authors： Klingemann HG,Eaves CJ,Barnett MJ,Eaves AC,Hogge DE,Nantel SH,Reece E,Shepherd JD,Sutherland HJ,Phillips GL

更新日期：1994-09-01 00:00:00

abstract：:Hepatic acute GvHD (aGvHD) is associated with high mortality owing to poor response to immunosuppressive therapy. The pathogenesis of hepatic aGvHD differs from that of other lesions, and specific risk factors related to pre-transplant liver conditions should be determined. We conducted a cohort study by using a Japan...

journal_title：Bone marrow transplantation

authors： Arai Y,Kanda J,Nakasone H,Kondo T,Uchida N,Fukuda T,Ohashi K,Kaida K,Iwato K,Eto T,Kanda Y,Nakamae H,Nagamura-Inoue T,Morishima Y,Hirokawa M,Atsuta Y,Murata M,GVHD working group of the Japan Society for Hematopoietic Ce

更新日期：2016-01-01 00:00:00

abstract：:The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some r...

journal_title：Bone marrow transplantation

authors： Smith SD,Bolwell BJ,Rybicki LA,Brown S,Dean R,Kalaycio M,Sobecks R,Andresen S,Hsi ED,Pohlman B,Sweetenham JW

更新日期：2007-08-01 00:00:00

abstract：:Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation. Pretransplant conditioning regimes cause release of proinflammatory cytokines that stimulate alloreactive donor T cells to attack recipient tissues. IL-10 has been shown to directly downregulate CD4+ T cells...

journal_title：Bone marrow transplantation

authors： Weston LE,Geczy AF,Briscoe H

更新日期：2006-01-01 00:00:00

abstract：:Intensive high-dose chemotherapy with peripheral blood progenitor cell (PBPC) transplantation is a common strategy for aggressive non-Hodgkin's lymphomas (NHL). A retrospective cost-effectiveness analysis of CD34+ cell dose was carried out. Between 1994 and 1998, 28 patients were included. Efficacy was measured by the...

journal_title：Bone marrow transplantation

authors： Limat S,Woronoff-Lemsi MC,Deconinck E,Racadot E,Jacquet M,Herve P,Cahn JY

更新日期：2000-05-01 00:00:00

abstract：:The current study evaluates the role of quantitative measurement of peripheral lymphocyte subsets, especially CD4+ helper T-cell recovery, in predicting transplant outcomes including overall survival (OS) and non-relapse mortality (NRM) after allogeneic stem cell transplantation. A total of 69 allogeneic recipients we...

journal_title：Bone marrow transplantation

authors： Kim DH,Sohn SK,Won DI,Lee NY,Suh JS,Lee KB

更新日期：2006-06-01 00:00:00